' 
SCIENTIFIC SCORE
Possibly Effective
Based on 46 Researches
7.5
USERS' SCORE
Good
Based on 29 Reviews
8
Supplement Facts
Serving Size: 2 Soft Gels
Amount Per Serving
%DV
Calories
30
Total Fat
2.5 g
3%**
Cholesterol
<5 mg
1%
Protein
<1 g
Vitamin E (as natural d-alpha tocopherol)
13.4 mg
89%
Norwegian Fish Oil
2.5 g
†
Total Omega-3 Fatty Acids*
1,600 mg
†
EPA (Eicosapentaenoic Acid)*
800 mg
†
DHA (Docosahexaenoic Acid)*
600 mg
†
Top Medical Research Studies
9
Omega-3 levels reduce heart failure
Association of Plasma Omega-3 Levels With Incident Heart Failure and Related Mortalities.
Significant positive health implications
We investigated the link between plasma omega-3 levels and the risk of heart failure (HF) in a large UK cohort study. Our analysis revealed that higher omega-3 levels were associated with a 21% lower chance of developing HF over nearly 14 years.
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
Read More
9
Omega-3 reduces cardiovascular risk
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial.
Findings show clear clinical relevance.
We observed the effects of icosapent ethyl on heart health in a significant clinical trial involving statin-treated patients at high risk for cardiovascular events. This post hoc analysis revealed that icosapent ethyl reduced major cardiovascular issues, regardless of whether patients had low-density lipoprotein cholesterol (LDL-C) levels below or above 55 mg/dL.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
Read More
9
EPA's role in diabetic heart health
Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy.
High relevance to cardiovascular disease
We explored the impact of eicosapentaenoic acid (EPA), a nutrient known for its heart benefits, on diabetic cardiomyopathy (DC), a condition leading to heart failure. Our study focused on diabetic mice and revealed that EPA plays a protective role against DC, particularly by reducing harmful M1-polarized macrophages in the heart.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
Read More
Most Useful Reviews
9.5
Improved health
I thoroughly enjoyed this product. After over a month of use, my health has improved significantly, boosting my immunity against viral diseases. My headaches have become less frequent, and my skin's condition has improved remarkably. The vascular mesh on my face has practically disappeared. I appreciate the small bonus package that is convenient to carry.
Read More
9.5
Supports heart
I have taken Omega 3 for many years, especially due to age-related cardiovascular disease. It helps control cholesterol, which is lacking in my diet. I chose Solgar for its optimal dosage and quality ingredients. I take two capsules every morning with breakfast, and it relieves inflammation. Despite their size, they are easy to swallow, and I recommend this product for its value.
Read More
9.5
Reduces cholesterol levels
Posh Omega ensures cardiovascular disease is a lesser risk by cleansing blood vessels of "bad" cholesterol and improving elasticity, thus normalising blood pressure and reducing cholesterol plaques. I’ve been taking it for three months.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 46 Researches
7.5
- All Researches
9
Omega-3 reduces cardiovascular risk
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial.
Findings show clear clinical relevance.
We observed the effects of icosapent ethyl on heart health in a significant clinical trial involving statin-treated patients at high risk for cardiovascular events. This post hoc analysis revealed that icosapent ethyl reduced major cardiovascular issues, regardless of whether patients had low-density lipoprotein cholesterol (LDL-C) levels below or above 55 mg/dL.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
Read More
9
Omega-3 improves heart function
The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis.
High relevance and statistical significance
We assessed how omega-3 fatty acids (PUFAs) can support heart failure management through a thorough network meta-analysis of 14 studies with nearly 9,100 participants.
Our findings revealed that high doses (2,000-4,000 mg/day) taken for at least one year significantly improved heart function, particularly the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter durations were not effective, and we found no major differences in safety measures like dropout rates or overall mortality between those taking omega-3 and those who were not.
Our findings revealed that high doses (2,000-4,000 mg/day) taken for at least one year significantly improved heart function, particularly the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter durations were not effective, and we found no major differences in safety measures like dropout rates or overall mortality between those taking omega-3 and those who were not.
Read More
9
Omega-3 levels reduce heart failure
Association of Plasma Omega-3 Levels With Incident Heart Failure and Related Mortalities.
Significant positive health implications
We investigated the link between plasma omega-3 levels and the risk of heart failure (HF) in a large UK cohort study. Our analysis revealed that higher omega-3 levels were associated with a 21% lower chance of developing HF over nearly 14 years.
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
Read More
9
Icosapent ethyl reduces cardiovascular risks
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial.
Study highlights treatment effectiveness
We explored the effectiveness of icosapent ethyl, a form of eicosapentaenoic acid, in reducing cardiovascular events among statin-treated patients who had high cardiovascular risk and controlled cholesterol levels.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
Read More
9
Eicosapentaenoic acid benefits heart health
The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis.
Focus on omega-3 effects
We explored the effectiveness of eicosapentaenoic acid (EPA), a type of omega-3 polyunsaturated fatty acid (PUFA), in managing heart failure. By analyzing data from multiple randomized controlled trials, we aimed to identify the best doses and treatment durations for EPA supplementation.
The findings from our network meta-analysis included 14 studies with nearly 9,000 participants, primarily older adults with heart failure. We discovered that high doses of omega-3 PUFAs, specifically between 2000 and 4000 mg per day for at least one year, significantly improved heart function. This was measured by an increase in the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter supplementation periods did not yield similar benefits. It's worth noting that EPA supplementation did not increase the risk of adverse events, as dropout rates and overall mortality were comparable to control groups.
Our study suggests that long-term, high-dose omega-3 supplementation shows promise for enhancing heart function in individuals with heart failure. Nonetheless, we believe that more in-depth clinical trials are necessary to confirm these results and ensure the findings are robust and reliable.
The findings from our network meta-analysis included 14 studies with nearly 9,000 participants, primarily older adults with heart failure. We discovered that high doses of omega-3 PUFAs, specifically between 2000 and 4000 mg per day for at least one year, significantly improved heart function. This was measured by an increase in the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter supplementation periods did not yield similar benefits. It's worth noting that EPA supplementation did not increase the risk of adverse events, as dropout rates and overall mortality were comparable to control groups.
Our study suggests that long-term, high-dose omega-3 supplementation shows promise for enhancing heart function in individuals with heart failure. Nonetheless, we believe that more in-depth clinical trials are necessary to confirm these results and ensure the findings are robust and reliable.
Read More
User Reviews
USERS' SCORE
Good
Based on 29 Reviews
8
- All Reviews
- Positive Reviews
- Negative Reviews
9.5
Improved health
I thoroughly enjoyed this product. After over a month of use, my health has improved significantly, boosting my immunity against viral diseases. My headaches have become less frequent, and my skin's condition has improved remarkably. The vascular mesh on my face has practically disappeared. I appreciate the small bonus package that is convenient to carry.
Read More
9.5
Supports heart
I have taken Omega 3 for many years, especially due to age-related cardiovascular disease. It helps control cholesterol, which is lacking in my diet. I chose Solgar for its optimal dosage and quality ingredients. I take two capsules every morning with breakfast, and it relieves inflammation. Despite their size, they are easy to swallow, and I recommend this product for its value.
Read More
9.5
Reduces cholesterol levels
Posh Omega ensures cardiovascular disease is a lesser risk by cleansing blood vessels of "bad" cholesterol and improving elasticity, thus normalising blood pressure and reducing cholesterol plaques. I’ve been taking it for three months.
8.8
Family health support
I regularly buy Omega from this company. The high dosage and good quality benefit our cardiovascular health without leaving a fishy aftertaste, only a slight citrus flavour.
8.8
Heart and diabetes assistance
I appreciate that omega-3 helps manage cardiovascular disease, lowers HDL cholesterol, and benefits individuals with pressure and diabetes by delaying their effects.
